Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Shepherd, L, Borges, ÁH, Harvey, R, Bower, M, Grulich, A, Silverberg, M, Weber, J, Ristola, M, Viard, J-P, Bogner, JR, Gargalianos-Kakolyris, P, Mussini, C, Mansinho, K, Yust, I, Paduta, D, Jilich, D, Smiatacz, T, Radoi, R, Tomazic, J, Plomgaard, P, Frikke-Schmidt, R, Lundgren, J, Mocroft, A & EuroSIDA in EuroCOORD 2018, 'The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people' HIV Medicine, pp. 90-101. https://doi.org/10.1111/hiv.12546

APA

Shepherd, L., Borges, Á. H., Harvey, R., Bower, M., Grulich, A., Silverberg, M., ... EuroSIDA in EuroCOORD (2018). The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. HIV Medicine, 90-101. https://doi.org/10.1111/hiv.12546

CBE

Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard J-P, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A, EuroSIDA in EuroCOORD. 2018. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. HIV Medicine. 90-101. https://doi.org/10.1111/hiv.12546

MLA

Vancouver

Author

Shepherd, L ; Borges, Á H ; Harvey, R ; Bower, M ; Grulich, A ; Silverberg, M ; Weber, J ; Ristola, M ; Viard, J-P ; Bogner, J R ; Gargalianos-Kakolyris, P ; Mussini, C ; Mansinho, K ; Yust, I ; Paduta, D ; Jilich, D ; Smiatacz, T ; Radoi, R ; Tomazic, J ; Plomgaard, Peter ; Frikke-Schmidt, R ; Lundgren, J ; Mocroft, A ; EuroSIDA in EuroCOORD. / The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. In: HIV Medicine. 2018 ; pp. 90-101.

Bibtex

@article{d081322b99664cb08107e6f5fea1c98b,
title = "The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people",
abstract = "OBJECTIVES: B-cell dysfunction and activation are thought to contribute to lymphoma development in HIV-positive people; however, the mechanisms are not well understood. We investigated levels of several markers of B-cell dysfunction [free light chain (FLC)-κ, FLC-λ, immunoglobulin G (IgG), IgA, IgM and IgD] prior to lymphoma diagnosis in HIV-positive people.METHODS: A nested matched case-control study was carried out within the EuroSIDA cohort, including 73 HIV-positive people with lymphoma and 143 HIV-positive lymphoma-free controls. Markers of B-cell dysfunction were measured in prospectively stored serial plasma samples collected before the diagnosis of lymphoma (or selection date in controls). Marker levels ≤ 2 and > 2 years prior to diagnosis were investigated.RESULTS: Two-fold higher levels of FLC-κ [odds ratio (OR) 1.84; 95{\%} confidence interval (CI) 1.19, 2.84], FLC-λ (OR 2.15; 95{\%} CI 1.34, 3.46), IgG (OR 3.05; 95{\%} CI 1.41, 6.59) and IgM (OR 1.46; 95{\%} CI 1.01, 2.11) were associated with increased risk of lymphoma > 2 years prior to diagnosis, but not ≤ 2 years prior. Despite significant associations > 2 years prior to diagnosis, the predictive accuracy of each marker was poor, with FLC-λ emerging as the strongest candidate with a c-statistic of 0.67 (95{\%} CI 0.58, 0.76).CONCLUSIONS: FLC-κ, FLC-λ and IgG levels were higher > 2 years before lymphoma diagnosis, suggesting that B-cell dysfunction occurs many years prior to lymphoma development. However, the predictive value of each marker was low and they are unlikely candidates for risk assessment for targeted intervention.",
keywords = "Journal Article",
author = "L Shepherd and Borges, {{\'A} H} and R Harvey and M Bower and A Grulich and M Silverberg and J Weber and M Ristola and J-P Viard and Bogner, {J R} and P Gargalianos-Kakolyris and C Mussini and K Mansinho and I Yust and D Paduta and D Jilich and T Smiatacz and R Radoi and J Tomazic and Peter Plomgaard and R Frikke-Schmidt and J Lundgren and A Mocroft and {EuroSIDA in EuroCOORD}",
note = "{\circledC} 2017 British HIV Association.",
year = "2018",
month = "2",
doi = "10.1111/hiv.12546",
language = "English",
pages = "90--101",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell Publishing Ltd",

}

RIS

TY - JOUR

T1 - The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

AU - Shepherd, L

AU - Borges, Á H

AU - Harvey, R

AU - Bower, M

AU - Grulich, A

AU - Silverberg, M

AU - Weber, J

AU - Ristola, M

AU - Viard, J-P

AU - Bogner, J R

AU - Gargalianos-Kakolyris, P

AU - Mussini, C

AU - Mansinho, K

AU - Yust, I

AU - Paduta, D

AU - Jilich, D

AU - Smiatacz, T

AU - Radoi, R

AU - Tomazic, J

AU - Plomgaard, Peter

AU - Frikke-Schmidt, R

AU - Lundgren, J

AU - Mocroft, A

AU - EuroSIDA in EuroCOORD

N1 - © 2017 British HIV Association.

PY - 2018/2

Y1 - 2018/2

N2 - OBJECTIVES: B-cell dysfunction and activation are thought to contribute to lymphoma development in HIV-positive people; however, the mechanisms are not well understood. We investigated levels of several markers of B-cell dysfunction [free light chain (FLC)-κ, FLC-λ, immunoglobulin G (IgG), IgA, IgM and IgD] prior to lymphoma diagnosis in HIV-positive people.METHODS: A nested matched case-control study was carried out within the EuroSIDA cohort, including 73 HIV-positive people with lymphoma and 143 HIV-positive lymphoma-free controls. Markers of B-cell dysfunction were measured in prospectively stored serial plasma samples collected before the diagnosis of lymphoma (or selection date in controls). Marker levels ≤ 2 and > 2 years prior to diagnosis were investigated.RESULTS: Two-fold higher levels of FLC-κ [odds ratio (OR) 1.84; 95% confidence interval (CI) 1.19, 2.84], FLC-λ (OR 2.15; 95% CI 1.34, 3.46), IgG (OR 3.05; 95% CI 1.41, 6.59) and IgM (OR 1.46; 95% CI 1.01, 2.11) were associated with increased risk of lymphoma > 2 years prior to diagnosis, but not ≤ 2 years prior. Despite significant associations > 2 years prior to diagnosis, the predictive accuracy of each marker was poor, with FLC-λ emerging as the strongest candidate with a c-statistic of 0.67 (95% CI 0.58, 0.76).CONCLUSIONS: FLC-κ, FLC-λ and IgG levels were higher > 2 years before lymphoma diagnosis, suggesting that B-cell dysfunction occurs many years prior to lymphoma development. However, the predictive value of each marker was low and they are unlikely candidates for risk assessment for targeted intervention.

AB - OBJECTIVES: B-cell dysfunction and activation are thought to contribute to lymphoma development in HIV-positive people; however, the mechanisms are not well understood. We investigated levels of several markers of B-cell dysfunction [free light chain (FLC)-κ, FLC-λ, immunoglobulin G (IgG), IgA, IgM and IgD] prior to lymphoma diagnosis in HIV-positive people.METHODS: A nested matched case-control study was carried out within the EuroSIDA cohort, including 73 HIV-positive people with lymphoma and 143 HIV-positive lymphoma-free controls. Markers of B-cell dysfunction were measured in prospectively stored serial plasma samples collected before the diagnosis of lymphoma (or selection date in controls). Marker levels ≤ 2 and > 2 years prior to diagnosis were investigated.RESULTS: Two-fold higher levels of FLC-κ [odds ratio (OR) 1.84; 95% confidence interval (CI) 1.19, 2.84], FLC-λ (OR 2.15; 95% CI 1.34, 3.46), IgG (OR 3.05; 95% CI 1.41, 6.59) and IgM (OR 1.46; 95% CI 1.01, 2.11) were associated with increased risk of lymphoma > 2 years prior to diagnosis, but not ≤ 2 years prior. Despite significant associations > 2 years prior to diagnosis, the predictive accuracy of each marker was poor, with FLC-λ emerging as the strongest candidate with a c-statistic of 0.67 (95% CI 0.58, 0.76).CONCLUSIONS: FLC-κ, FLC-λ and IgG levels were higher > 2 years before lymphoma diagnosis, suggesting that B-cell dysfunction occurs many years prior to lymphoma development. However, the predictive value of each marker was low and they are unlikely candidates for risk assessment for targeted intervention.

KW - Journal Article

U2 - 10.1111/hiv.12546

DO - 10.1111/hiv.12546

M3 - Journal article

SP - 90

EP - 101

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

ER -

ID: 52055339